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Active pharmaceutical ingredients (APIs), as most of medicines, are obtained through chemical synthesis, using 
highly reactive reagents and usually, low levels of reagents, fractions of catalysts, or by-products are present in 
the final API or drug product as impurities. Some of these impurities have unwanted toxicities, including 
genotoxicity and carcinogenicity, and therefore related API administration risks for patient’s health has become 
an increasing concern of pharmaceutical companies, regulatory authorities, patients and doctors. European 
Medicines Agency (EMA) was the first agency to implement guidelines to control genotoxic impurities (GTIs), 
followed by the Food and Drug Administration (FDA). Both authorities agreed on setting as “Threshold of 
Toxicological Concern” (TTC) a limit at 1.5 micrograms per day for known and potential carcinogens [1,2]. 
Herein we report an approach based on the thermal treatment of a polybenzimidazole polymer providing novel 
adsorbent properties for genotoxic removal to purify API post-reaction streams. These novel adsorbents were 
tested for GTIs, such as methyl p-toluenesulfonate, p-toluenesulfonic acid, 4,4-dimethylamino pyridine and 
ethanesulfonyl chloride, from API solutions of Mometasone furoate (Meta). The current work will present a 
strategy of a hybrid process combining organic solvent nanofiltration (OSN) of API post-reaction streams with 
the adsorbers studied. The aim to include an adsorber stage, after the OSN operation, is to polish the retentate 
API solution for further purification or/and recovery of API lost through the permeate stream. Results will 
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